Georges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, Nishita Tripathi, Beverly Chigarira, Divyam Goel, Blake Nordblad, Taylor R McFarland, Arshit Narang, Ayana Srivastava, Clara Tandar, Emre Dal, Yeonjung Jo, Gliceida Galarza Fortuna, Vinay Mathew Thomas, Kamal K Sahu, Haoran Li, Benjamin L Maughan, Umang Swami, Neeraj Agarwal
BACKGROUND: Androgen deprivation therapy (ADT) intensification (ADTi) (i.e., ADT with androgen receptor pathway inhibitor or docetaxel, or both) has significantly improved survival outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of prior ADTi in the mHSPC setting on the disease presentation and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) is not well characterized. In this study, our objective was to compare the disease characteristics and survival outcomes of patients with new mCRPC with respect to receipt of intensified or nonintensified ADT in the mHSPC setting...
April 1, 2024: Prostate